Dolutegravir is an integrase inhibitor used to treat HIV-1 infection by preventing viral replication. It is grouped under the following drug class(es): HIV-1 Integrase Inhibitors. Its therapeutic use is listed as anti-infectives and antivirals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Tivicay and Soltegravir. Its PubChem CID is 54726191.
Dolutegravir
| CAS No | 1051375-16-6 |
|---|---|
| Molecular Formula | C20H19F2N3O5 |
| Molecular Weight | 419.4 g/mol |
| Synonyms | (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Dolutegravir is an integrase inhibitor used to treat HIV-1 infection by preventing viral replication. It is grouped under the following drug class(es): HIV-1 Integrase Inhibitors.
The listed CAS number is 1051375-16-6.
The listed molecular formula is C20H19F2N3O5.
The listed molecular weight is 419.4 g/mol.
(3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide.
The source lists Tivicay and Soltegravir.